Targeting metabolic plasticity in breast cancer cells via mitochondrial complex I modulation

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 43-56

  Xu, Qijin ^a   Biener Ramanujan, Eva ^a   Yang, Wei ^a   Ramanujan, V Krishnan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antioxidant pathway; Breast cancer; Catalase; Metabolic plasticity; Metabolic switch; Mitochondrial complex I

Indexed keywords

CATALASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SUPEROXIDE DISMUTASE; PROTEOME; UNCOUPLING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL METABOLISM; CONTROLLED STUDY; DRUG TARGETING; ENZYME REGULATION; EVOLUTIONARY ADAPTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR SIGNALING; METABOLIC PLASTICITY; METABOLISM; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; TREATMENT OUTCOME; TUMOR XENOGRAFT; ADAPTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX I; FEMALE; HETEROGRAFTS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MITOCHONDRIA; OXIDATION-REDUCTION; PROTEOME; PROTEOMICS; ROTENONE; SIGNAL TRANSDUCTION; TUMOR BURDEN; UNCOUPLING AGENTS;

EID: 84925486756     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3304-8     Document Type: Article

References (29)

1. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P (2013) The Warburg effect: insights from the past decade. Pharmacol Ther 137(3):318–330. doi:10.1016/j.pharmthera.2012.11.003
2. Kim S, Kim do H, Jung WH, Koo JS (2013) Metabolic phenotypes in triple-negative breast cancer. Tumour Biol: J Int Soc Oncodevelop Biol Med 34(3):1699–1712. doi:10.1007/s13277-013-0707-1
3. Soga T (2012) Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. doi:10.1111/cas.12085
4. Schulze A, Harris AL (2012) How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491(7424):364–373. doi:10.1038/nature11706
5. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013
6. Tennant DA, Duran RV, Boulahbel H, Gottlieb E (2009) Metabolic transformation in cancer. Carcinogenesis 30(8):1269–1280
7. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Develop 18(1):54–61
8. Kroemer G (2006) Mitochondria in cancer. Oncogene 25(34):4630–4632
9. Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269–270
10. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033
11. Suhane S, Kanzaki H, Arumugaswami V, Murali R, Ramanujan VK (2013) Mitochondrial NDUFS3 regulates ROS-mediated onset of metabolic switch in transformed cells. Biol Open 2(3):295–305. doi:10.1242/bio.20133244
12. Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, Gay LJ, Yagi T, Felding-Habermann B (2013) Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J Clin Investig 123(3):1068–1081. doi:10.1172/JCI64264
13. Ramanujan VK (2014) Metabolic imaging in multiple time scales. Methods 66(2):222–229. doi:10.1016/j.ymeth.2013.08.027
14. Suhane S, Ramanujan VK (2011) Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. Biochem Biophys Res Commun 414(1):73–78. doi:10.1016/j.bbrc.2011.09.024
15. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteom: MCP 1(5):376–386
16. Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359–362. doi:10.1038/nmeth.1322
17. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 10(4):1794–1805. doi:10.1021/pr101065j
18. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26(12):1367–1372. doi:10.1038/nbt.1511
19. Margoliash E, Novogrodsky A (1958) A study of the inhibition of catalase by 3-amino-1:2:4:-triazole. Biochem J 68(3):468–475
20. Margoliash E, Novogrodsky A, Schejter A (1960) Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase. Biochem J 74:339–348
21. Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F (2011) Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs “fertilizer”. Cell Cycle 10(15):2440–2449
22. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277(26):23111–23115
23. Owens KM, Kulawiec M, Desouki MM, Vanniarajan A, Singh KK (2011) Impaired OXPHOS complex III in breast cancer. PLoS ONE 6(8):e23846. doi:10.1371/journal.pone.0023846
24. Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Tanowitz HB, Pestell RG, Sotgia F, Lisanti MP (2012) Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1alpha and HIF2alpha in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle 11(17):3280–3289. doi:10.4161/cc.21643
25. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8(23):3984–4001
26. Cardaci S, Desideri E, Ciriolo MR (2012) Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr 44(1):17–29. doi:10.1007/s10863-012-9422-7
27. Pedersen PL (2007) Warburg, me and Hexokinase 2: multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg effect”, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(3):211–222
28. Goh J, Enns L, Fatemie S, Hopkins H, Morton J, Pettan-Brewer C, Ladiges W (2011) Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer 11:191. doi:10.1186/1471-2407-11-191
29. Min JY, Lim SO, Jung G (2010) Downregulation of catalase by reactive oxygen species via hypermethylation of CpG island II on the catalase promoter. FEBS Lett 584(11):2427–2432. doi:10.1016/j.febslet.2010.04.048